Nektar Therapeutics (NKTR) compared with its closest peers (AGIO, QTTB, XOMA, OCUL, LXRX). Peer set by Pharmaceutical Products; 10 comparable drugmakers. First-party data.
Agios Pharmaceuticals, Q32 Bio, XOMA Royalty, Ocular Therapeutix, Lexicon Pharmaceuticals, Journey Medical, Tango Therapeutics, Nuvation Bio, Fortress Biotech and Enanta Pharmaceuticals share Nektar Therapeutics's sub-industry, pharmaceutical makers.
| Company | Market Cap | P/E |
|---|---|---|
| Agios Pharmaceuticals, Inc. (AGIO) | $1.97B | -3.8 |
| Q32 Bio Inc. (QTTB) | $270.79M | 1.4 |
| XOMA Royalty Corp. (XOMA) | $505.65M | 16.8 |
| Ocular Therapeutix, Inc. (OCUL) | $2.43B | -8.5 |
| Lexicon Pharmaceuticals, Inc. (LXRX) | $1.03B | -8.1 |
| Journey Medical Corporation (DERM) | $213.21M | -16.4 |
| Tango Therapeutics, Inc. (TNGX) | $3.46B | -10.2 |
| Nuvation Bio Inc. (NUVB) | $2.43B | -14.9 |
| Fortress Biotech, Inc. (FBIO) | $95.44M | 0.9 |
| Enanta Pharmaceuticals, Inc. (ENTA) | $390.28M | -2.8 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
NKTR overview · NKTR earnings · NKTR financials · NKTR KPIs · NKTR documents · NKTR ownership
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.